Elif Korkmaz - Specialist Sales - US Healthcare AC elif.korkmaz@jpmorgan.com J.P. Morgan Securities LLC North America Specialist Sales J P M O R G A N 04 August 2026 JPM | US Healthcare: First Takes: MRK, PFE, IDXX, BRKR, WAT, RVTY, RYTM, BNTX, HSIC. Recaps: JAZZ Mgmt Call Today, VRTX, DHR CEO Change, MedTech Deals, INSP, ALHC, CNC, Facilities, MRNA. MIRM/ BCRX, ACAD, CYTK, IMVT, TGTX, ROIV, ORIC, VERA, Upcoming Mgmt Calls : CVS / MCK / COR / CAH and more... Elif Korkmaz +1 (212) 622 2949 elif.korkmaz@jpmor ...

On this morning's call (8:00am ET; Webcast here), we expect key focus areas to include: | M Downloaded by zouguanzhong@cramc.hk | Not for redistribution without written consent of Morgan Stanley | | | | --- | --- | --- | --- | | | | | Update | | August 4, 2026 11:52 AM GMT | | | | | Rhythm Pharmaceuticals Inc North America | Morgan Stanley & Co. LLC Michael E Ulz | | | | | Equity Analyst | | | | 2Q26 Quick Take: Imcivree Beat, | | Mike.Ulz@morganstanley.com | +1 212 761-4650 | | | Rohit Bhasin | | | | | Res ...

Flash | 04 Aug 2026 07:48:22 ET │ 11 pages Rhythm Pharmaceuticals (RYTM.O) 2Q26 First Take: HO Launch Builds on Early Momentum CITI'S TAKE Rhythm reported >400 start forms (up from >150 on 1Q26 call) have been received in the first 14 weeks of the Imcivree launch in HO, with scripts written by ~300 prescribers. WW Imcivree revenue was $71.3M for the quarter, representing 19% QoQ growth that beat our estimate of $66.6M and Factset consensus of $66.7M. US Imcivree revenue was $51.0M, an increase of 38% QoQ dr ...